Rubella Articles & Analysis: Older
5 news found
– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine – ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. ...
A universal vaccine for influenza could be administered prior to need, potentially issued alongside standard childhood vaccinations such as measles/mumps/rubella and varicella. And a shelf-stable delivery method would enable safe storage and distribution worldwide. ...
Further longer-term stability studies are underway, and the Company is planning the immunogenicity studies needed to determine the next development steps to progress the novel vaccine formulations towards clinical trials. Measles and Rubella vaccines are typically maintained in a lyophilized (freeze-dried) form that requires reconstitution in solution prior to injection using a ...
Though they are still used to address previously common infectious diseases (especially “childhood diseases” such as measles, mumps, rubella, and chicken pox), these vaccines must be handled and stored carefully. ...
(Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies including a Phase 1 trial of an FDA-approved seasonal ...